Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model
<p>Abstract</p> <p>Background</p> <p>The purpose of this study was to evaluate the biodistribution and toxicity of amphotericin B (AmB) following multiple oral administrations of a novel tropically stable lipid-based formulation (iCo-010).</p> <p>Methods<...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-08-01
|
Series: | Lipids in Health and Disease |
Subjects: | |
Online Access: | http://www.lipidworld.com/content/10/1/135 |
id |
doaj-871db15d866241399a3bbc778a8afec4 |
---|---|
record_format |
Article |
spelling |
doaj-871db15d866241399a3bbc778a8afec42020-11-25T01:32:41ZengBMCLipids in Health and Disease1476-511X2011-08-0110113510.1186/1476-511X-10-135Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse modelOwen DavidZhao JinyingWasan Ellen KLin MollyGershkovich PavelSivak OlenaClement John GWasan Kishor M<p>Abstract</p> <p>Background</p> <p>The purpose of this study was to evaluate the biodistribution and toxicity of amphotericin B (AmB) following multiple oral administrations of a novel tropically stable lipid-based formulation (iCo-010).</p> <p>Methods</p> <p>BALB/c mice were allocated into six groups: oral iCo-010 twice daily for 5 days in the dose of 20, 10, 5 and 2.5 mg/kg; vehicle control; and intravenous boluses of Fungizone<sup>® </sup>2 mg/kg once daily for 5 days. The animals were sacrificed 12 h following the last administration and blood and tissues were collected.</p> <p>Results</p> <p>The plasma concentrations of AmB were similar to previously reported after administration of iCo-009. Somewhat lower concentrations of AmB were detected in reticulo-endothelial system in the case of iCo-010 when compared with iCo-009. The concentration in kidney was higher with iCo-010 than with iCo-009. The creatinine levels in all oral treatment groups were in a normal range as in the case of iCo-009. Administration of Fungizone<sup>® </sup>resulted in elevated plasma creatinine levels. Histopathology analysis detected no GI, liver or kidney toxicity following multiple dose oral administration of iCo-010. Fungizone<sup>® </sup>treatment induced necrotic changes in hepatic and kidney tissues.</p> <p>Conclusions</p> <p>Given the tropical stability of iCo-010, near identical activity against visceral leishmaniasis and significant concentrations in target organs this formulation has a potential to become a treatment of choice in tropical developing countries.</p> http://www.lipidworld.com/content/10/1/135Lipid-based formulationIntestinal absorptionNephrotoxicityTissue distributionAmphotericin B |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Owen David Zhao Jinying Wasan Ellen K Lin Molly Gershkovich Pavel Sivak Olena Clement John G Wasan Kishor M |
spellingShingle |
Owen David Zhao Jinying Wasan Ellen K Lin Molly Gershkovich Pavel Sivak Olena Clement John G Wasan Kishor M Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model Lipids in Health and Disease Lipid-based formulation Intestinal absorption Nephrotoxicity Tissue distribution Amphotericin B |
author_facet |
Owen David Zhao Jinying Wasan Ellen K Lin Molly Gershkovich Pavel Sivak Olena Clement John G Wasan Kishor M |
author_sort |
Owen David |
title |
Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model |
title_short |
Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model |
title_full |
Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model |
title_fullStr |
Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model |
title_full_unstemmed |
Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model |
title_sort |
tropically stable novel oral lipid formulation of amphotericin b (ico-010): biodistribution and toxicity in a mouse model |
publisher |
BMC |
series |
Lipids in Health and Disease |
issn |
1476-511X |
publishDate |
2011-08-01 |
description |
<p>Abstract</p> <p>Background</p> <p>The purpose of this study was to evaluate the biodistribution and toxicity of amphotericin B (AmB) following multiple oral administrations of a novel tropically stable lipid-based formulation (iCo-010).</p> <p>Methods</p> <p>BALB/c mice were allocated into six groups: oral iCo-010 twice daily for 5 days in the dose of 20, 10, 5 and 2.5 mg/kg; vehicle control; and intravenous boluses of Fungizone<sup>® </sup>2 mg/kg once daily for 5 days. The animals were sacrificed 12 h following the last administration and blood and tissues were collected.</p> <p>Results</p> <p>The plasma concentrations of AmB were similar to previously reported after administration of iCo-009. Somewhat lower concentrations of AmB were detected in reticulo-endothelial system in the case of iCo-010 when compared with iCo-009. The concentration in kidney was higher with iCo-010 than with iCo-009. The creatinine levels in all oral treatment groups were in a normal range as in the case of iCo-009. Administration of Fungizone<sup>® </sup>resulted in elevated plasma creatinine levels. Histopathology analysis detected no GI, liver or kidney toxicity following multiple dose oral administration of iCo-010. Fungizone<sup>® </sup>treatment induced necrotic changes in hepatic and kidney tissues.</p> <p>Conclusions</p> <p>Given the tropical stability of iCo-010, near identical activity against visceral leishmaniasis and significant concentrations in target organs this formulation has a potential to become a treatment of choice in tropical developing countries.</p> |
topic |
Lipid-based formulation Intestinal absorption Nephrotoxicity Tissue distribution Amphotericin B |
url |
http://www.lipidworld.com/content/10/1/135 |
work_keys_str_mv |
AT owendavid tropicallystablenovelorallipidformulationofamphotericinbico010biodistributionandtoxicityinamousemodel AT zhaojinying tropicallystablenovelorallipidformulationofamphotericinbico010biodistributionandtoxicityinamousemodel AT wasanellenk tropicallystablenovelorallipidformulationofamphotericinbico010biodistributionandtoxicityinamousemodel AT linmolly tropicallystablenovelorallipidformulationofamphotericinbico010biodistributionandtoxicityinamousemodel AT gershkovichpavel tropicallystablenovelorallipidformulationofamphotericinbico010biodistributionandtoxicityinamousemodel AT sivakolena tropicallystablenovelorallipidformulationofamphotericinbico010biodistributionandtoxicityinamousemodel AT clementjohng tropicallystablenovelorallipidformulationofamphotericinbico010biodistributionandtoxicityinamousemodel AT wasankishorm tropicallystablenovelorallipidformulationofamphotericinbico010biodistributionandtoxicityinamousemodel |
_version_ |
1725080452187815936 |